DRUG Bright Minds Biosciences Inc.

XNAS 20.55 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DRUG $20.55 —

What changed

Recent filings, trades and moves
Key stats
$20.55
52-Week Range
$17.40 – $123.75
YTD
-75.37%
IV Rank (30D)
86.31
Straddle Price
$5.12
P/C Vol Ratio
0.22
Market Cap
$0.2B
Open
$20.93
Day Range
$20.34 – $21.29
Volume
75,637
Prev Close
$20.76
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY2.34
Cost of Equity (CAPM)16.22% (VRP-adj)
WACC16.26%
Volatility Risk Premium-40.6pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Book / Price26.5%
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$46.25 (Market Anchor value)
SMA 20 / Bollinger Mid$33.38
Bollinger Width / SMA20181.7% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ANRO, ATAI, CMPS, DFTX, HELP, NBIX, NRXP, RLMD
60-Day Conviction
75%
20-Day Fair Value
≈ by Dec 18, 2026
$20.61
α +1.3% rank 97%
conviction
96%
40-Day Fair Value
≈ by Jan 18, 2027
$20.86
α +2.5% rank 95%
conviction
95%
60-Day Fair Value
≈ by Feb 16, 2027
$20.75
α +2.0% rank 90%
conviction
75%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $22.82 12% median 4.2× · 5 peers
Peer P/S n/a 0%
Market Anchor (SMA50) $46.25 65% stability 85% (BB-width)
Options Expected (B-L 30d) $19.17 23% 12 strikes · skew +0.34
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.2B
Employees
25
List Date
2021-03-08
CIK
0001827401
Next Earnings
2026-12-22
EPS Forecast
($1.07)
Homepage
https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan---27.89%-7.78%17.48%-17.30%-6.84%-8.47%
Feb---15.73%-19.70%-16.28%-0.03%6.59%-9.03%
Mar---26.71%-26.03%-31.82%3.29%-11.88%-18.63%
Apr---38.08%38.02%-30.07%-14.98%22.63%-4.50%
May--20.03%2.55%16.35%-15.25%1.28%4.99%
Jun---24.56%3.00%-9.62%-7.80%-13.35%-10.47%
Jul--24.71%38.92%10.47%27.05%8.77%21.98%
Aug--110.99%-45.29%-7.83%15.63%-2.78%14.14%
Sep---22.64%-26.61%7.83%56.34%-29.67%-2.95%
Oct---17.50%-11.18%4154.55%-5.52%11.73%826.42%
Nov-49.52%10.13%-2.19%-8.68%36.03%-20.80%*-5.84%
Dec-17.88%-35.09%0.70%-22.62%11.09%---12.76%
Total-58.55%-70.02%-61.03%1527.70%86.03%-38.03%231.02%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $31.76
SMA 50: $45.36
SMA 200: $68.99
Current: $20.37
EMA 12: $24.87
EMA 26: $33.14
MACD: -8.2711 | Signal: -0.0893
BEARISH
ADX (14): 45.69
STRONG TREND
+DI: 10.56
−DI: 40.67

Momentum Oscillators

RSI (14): 26.76
OVERSOLD
Stoch %K: 13.29
Stoch %D: 11.52
Williams %R: -76.31

Volume & Volatility

BB Upper: $61.23
BB Lower: $2.30
NEUTRAL
OBV: -6,250,769
Vol SMA 20: 283,546
Vol ROC: -82.80%
ATR: $3.76
True Range: $0.95
HV 20: 282.8%
HV 30: 236.5%
HV 60: 169.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before DRUG’s Aug 17 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Positive news sentiment surrounding recent announcements and presentations
  • Strong technical signals indicating a potential trend continuation

Primary Risks:

  • High volatility, with beta above 1.5, suggesting increased risk
  • Negative earnings surprise or guidance could lead to a sharp correction

Investment Thesis: The stock has been trending upward, driven by positive news sentiment and strong technical signals. While high volatility remains a concern, the stock's momentum and recent announcements suggest potential for continued growth.

Recent News Sentiment Impact: Positive headlines surrounding presentations and public offerings have contributed to the stock's upward trend.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Uptrend Medium-term (1-3 months): Uptrend Long-term (3-12 months): Uptrend

Support/Resistance Levels:

  • SMA 20: $75.34 (support)
  • EMA 12: $77.10 (resistance)

Momentum Signals:

  • RSI interpretation: Neutral (60.08), indicating no clear buy or sell signal
  • MACD signal: Bullish, with a bullish crossover above the signal line
  • Bollinger Bands position: Squeeze, indicating potential breakout

Volume Analysis: Volume SMA 20: 200028.45 (indicating increasing volume) On-Balance Volume (OBV): 142118787.56 (suggesting strong buying pressure)

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines surrounding presentations, public offerings, and pipeline developments have driven the stock's upward trend.

Sentiment Assessment: POSITIVE Catalyst Identification:

  • Upcoming presentations and conferences
  • Product launches and pipeline updates
  • Regulatory approvals (not applicable in this case)

Market Narrative: News sentiment aligns with technical signals, suggesting a potential trend continuation.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta >1.5) Volatility Regime: Current volatility is high compared to historical levels Options Market Signals: IV rank: 23.0% (Low), indicating historically low volatility

  • Put/Call Volume Ratio: Neutral sentiment, with more calls than puts

Downside Protection: Support level at SMA 20 ($75.34) and potential for a mean reversion if the stock pulls back.

Market Context & Positioning

Sector Performance: Relative strength vs sector/market (outperforming) Institutional Activity: Volume patterns suggesting institutional interest Correlation Analysis: Stock moves relatively strongly with market (R-squared: 0.32)

Relative Valuation: Positioned within a trading range, with potential for breakout or mean reversion.

Key Levels & Action Items

Critical Price Levels:

  • Support level at SMA 20 ($75.34)
  • Resistance level at EMA 12 ($77.10)

Breakout/Breakdown Levels:

  • Upper band of Bollinger Bands: $81.81 (potential resistance)
  • Lower band of Bollinger Bands: $68.87 (potential support)

Time-Sensitive Catalysts:

  • Upcoming presentations and conferences
  • Product launches and pipeline updates

Risk Management: Stop-loss levels at SMA 20 ($75.34) and position sizing considerations.

This comprehensive analysis provides a detailed assessment of the stock's technical, news, and risk characteristics. The report highlights key drivers, primary risks, and potential catalysts, while also outlining critical price levels, breakout/breakdown levels, and time-sensitive events.

Generated
Earnings History
1 of 1 under expected move
Avg Expected Move
6.98%
Avg Actual Move
5.74%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-08-17 unknown 6.98% 5.74% 0.82x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DRUG Options Activity & IV Rank

DRUG IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 110.9%
7-DTE IV: —
Expected Move: $5.12
7-DTE Move: $4.90
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 252
Put Volume: 55
P/C Volume: 0.218
BULLISH
Call OI: 476
Put OI: 69
P/C OI: 0.145
Total OI: 545

ATM Options Pricing

ATM Call: $2.67
ATM Put: $2.45
Call %: 13.0%
Put %: 11.9%

Chain Summary

Chain Volume: 307
Chain OI: 545
Last Updated: 11/19/2026

DRUG Implied Volatility

30-day IV
110.9%
Nov 19
IV rank
86High
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much DRUG actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 9th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
9%
vs own history
GEX tilt
-0.52
OI-weighted, today
Vanna tilt
+0.67
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +0.67: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 5 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 107.7% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)86.3HighNov 19

Embed DRUG IV rank

DRUG's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$5.12Nov 19
Beta Analysis

Risk Metrics

Beta: 1.3501
Alpha: -72.74%
Correlation: 0.2155
R-Squared: 4.6%
Stock Volatility: 86.2%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own DRUG
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$23.0M
0.04%
#547 of 1945new13F
Millennium Management Hedge fund
Izzy Englander
$4.7M
0.00%
#2090 of 3716+26.3%13F
Citadel Hedge fund
Ken Griffin
$4.7M
0.00%
#2155 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

DRUG Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 6,878,051 (as of 2025-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

110 filers9,213,266 shares$608.17M value133.95% of float
# Filer Shares Value % of Total % of Float Period
1 Jupiter Topco LLC 1,349,107 $94.82M 15.59% 19.61% 2026-06-30
2 Cormorant Asset Management, LP 900,000 $63.18M 10.39% 13.09% 2026-06-30
3 Vestal Point Capital, LP 545,000 $38.26M 6.29% 7.92% 2026-06-30
4 BRAIDWELL LP 483,822 $33.96M 5.58% 7.03% 2026-06-30
5 BlackRock, Inc. Custodian 651,794 $32.47M 5.34% 9.48% 2026-09-30
6 Driehaus Capital Management LLC 433,377 $30.42M 5.00% 6.30% 2026-06-30
7 Balyasny Asset Management L.P. 345,053 $24.22M 3.98% 5.02% 2026-06-30
8 ADAGE CAPITAL PARTNERS GP, L.L.C. 335,000 $23.52M 3.87% 4.87% 2026-06-30
9 Point72 Asset Management, L.P. 327,416 $22.98M 3.78% 4.76% 2026-06-30
10 Vivo Capital, LLC 417,879 $20.82M 3.42% 6.08% 2026-09-30
11 DEERFIELD MANAGEMENT COMPANY, L.P. 283,000 $19.87M 3.27% 4.11% 2026-06-30
12 RA CAPITAL MANAGEMENT, L.P. 265,000 $18.60M 3.06% 3.85% 2026-06-30
13 Parkman Healthcare Partners LLC 205,053 $14.39M 2.37% 2.98% 2026-06-30
14 MPM BioImpact LLC 202,114 $14.19M 2.33% 2.94% 2026-06-30
15 Wellington Management Group LLP Custodian 171,315 $12.03M 1.98% 2.49% 2026-06-30
16 Goldman Sachs Group Inc Custodian 133,689 $9.38M 1.54% 1.94% 2026-06-30
17 SEVEN GRAND MANAGERS, LLC 120,000 $8.42M 1.39% 1.74% 2026-06-30
18 GREAT POINT PARTNERS LLC 109,603 $7.69M 1.27% 1.59% 2026-06-30
19 ORBIMED ADVISORS LLC 93,000 $6.53M 1.07% 1.35% 2026-06-30
20 ACUTA CAPITAL PARTNERS, LLC 92,745 $6.51M 1.07% 1.35% 2026-06-30
21 EVENTIDE ASSET MANAGEMENT, LLC 130,013 $6.48M 1.06% 1.89% 2026-09-30
22 Ikarian Capital, LLC 88,951 $6.24M 1.03% 1.29% 2026-06-30
23 State Street Corp 122,150 $6.09M 1.00% 1.78% 2026-09-30
24 Sio Capital Management, LLC 73,952 $5.19M 0.85% 1.08% 2026-06-30
25 Geode Capital Management, LLC Custodian 104,059 $5.18M 0.85% 1.51% 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

DRUG Insider Trading (Form 4)

Latest: 2024-11-06
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2024-11-06 Bihua Chen 10%+ Owner Buy (P) +184,331 $21.70 $4.00M EDGAR
2024-10-17 Bihua Chen 10%+ Owner Buy (P) +422,591 $7.65 $3.23M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DRUG Board & Officers

As of SEC filings through Apr 30, 2026
Changes in the last 10 years (6)
Apr 30, 2026Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner
Apr 30, 2026Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner
Apr 30, 2026Bihua Chen reported in an SEC filing no longer being a 10% owner
Oct 15, 2024Cormorant Global Healthcare Master Fund, LP became a 10% owner
Oct 15, 2024Cormorant Asset Management, LP became a 10% owner
Oct 15, 2024Bihua Chen became a 10% owner
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
20 ETFs hold DRUG
20 shown · $11.79M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $3.8M $75.0B 2026-11-17
2 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $2.3M — 2026-10-31
3 PSIL AdvisorShares Psychedelics ETF Nport 3.84% $1.7M — 2026-06-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.01% $1.4M $13.5B 2026-11-17
5 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.02% $1.2M $6.6B 2026-11-17
6 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.04% $443,836 $1.2B 2026-11-17
7 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.03% $424,171 — 2026-10-31
8 GWX State Street® SPDR® S&P® International Small Cap ETF SPDR (State Street) 0.02% $191,955 $877.8M 2026-11-17
9 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $128,167 $3.1B 2026-11-17
10 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.01% $126,793 $1.0B 2026-11-17
11 RSSL Global X Russell 2000 ETF Global X 0.01% $68,923 — 2026-11-18
12 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $42,517 $19.9B 2026-11-17
13 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $32,273 — 2026-10-31
14 IBRN iShares Neuroscience and Healthcare ETF iShares (BlackRock) 0.25% $20,982 $8.2M 2026-11-17
15 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $8,262 — 2026-11-18
16 URTY ProShares UltraPro Russell2000 ProShares 0.00% $5,771 — 2026-11-18
17 UWM ProShares Ultra Russell2000 ProShares 0.00% $3,778 — 2026-11-18
18 RESM Columbia Research Enhanced Small Cap ETF Nport 0.02% $632 — 2026-06-30
19 HDG ProShares Hedge Replication ETF ProShares 0.00% $187 — 2026-11-18
20 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.00% $42 — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—

DRUG vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
NBIX Neurocrine Biosciences Inc $16.5B 23.6 +38.0% +13.0% 38
DFTX Definium Therapeutics, Inc. Common Share $4.0B — — +85.3% 32
ATAI AtaiBeckley Inc. Common Stock $2.7B — +811.8% +89.9% —
CMPS COMPASS Pathways Plc American Depository $1.2B — — +22.9% 39
ANRO Alto Neuroscience Inc. $1.0B — — +55.3% 61
HELP Helus Pharma Inc. Common Stock $550M — — −12.3% 33
RLMD Relmada Therapeutics, Inc. Common Stock $305M — — −33.8% 11
DRUG Bright Minds Biosciences Inc. Common Sto $205M — — −75.5% 84
NRXP NRX Pharmaceuticals, Inc. Common Stock $124M — — +5.7% 17
Peer median $1.1B 23.6 +424.9% +17.9% 33

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
801.24K
SI % of Float
1.45%
Days to Cover
7.91
Short Vol Ratio
41.9%
Free Float
55.43M
Float %
70.2%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-10-02